The ASPIRE II Study
Research type
Research Study
Full title
ASPIRE II: Supporting Antibiotic Stewardship in Primary Care via POCT
IRAS ID
322984
Contact name
Mark Williams
Contact email
Sponsor organisation
University of South Wales
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
0 years, 9 months, 1 days
Research summary
Acute respiratory tract infections account for a large number of visits to Primary Care practices in the NHS. Clinicians regularly struggle to distinguish between viral and bacterial infections as the symptoms are non specific. A result of this is that GP's routinely prescribe antibiotics based off a subjective clinical decision, thus many patients are wrongly prescribed antibiotics as a measure of precaution.
The FebriDx assay (POC test assay)is a POC immunoassay that can be used as a clinicians decision tool, providing a readable result within 10 minutes. The POC test assay can distinguish between viral and bacterial infections with MXA and CRP biomarkers.
The study will be a continuation of the ASPIRE study, which was a blinded observational study that determined the FebriDx POC test was a valuable diagnostic tool in Primary Care practice.
The purpose of the ASPIRE II un-blinded study is to determine if the FebriDx POC test is more effective when used as a clinical decision making tool at consultation from GP's, by reducing antibiotic over-prescribing.
REC name
West Midlands - Black Country Research Ethics Committee
REC reference
23/WM/0048
Date of REC Opinion
23 Mar 2023
REC opinion
Further Information Favourable Opinion